Evidence map›Paper›PMID 26381193›Full record

Observational studyAddiction (Abingdon, England)2016

Declining and rebounding unhealthy alcohol consumption during the first year of HIV care in rural Uganda, using phosphatidylethanol to augment self-report.

Judith A Hahn, Nneka I Emenyonu, Robin Fatch, Winnie R Muyindike, Allen Kekiibina, Adam W Carrico, Sarah Woolf-King, Stephen Shiboski

2 registry-linked trialsAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Addiction (Abingdon, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03302299 phase4completednot on this mapstarted 2017, after this paper: background citation

URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2021Enrolled302ConditionsTuberculosis, HIV/AIDS, Alcohol AbuseArmsIsoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet
NCT05756790 nacompletednot on this mapstarted 2023, after this paper: background citation

Couple-Based Motivational Interviewing With Mobile Breathalyzers to Reduce Alcohol Use in South Africa

TypeinterventionalSponsorUniversity of California, San FranciscoRan2023 to 2024Enrolled186ConditionsHIV/AIDS, Alcohol AbuseArmsMotivational Interviewing, Motivational Interviewing plus Breathalyzer
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Judith A HahnUniversity of California, Department of Medicine, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2697-8264
Nneka I EmenyonuUniversity of California, Department of Medicine, San Francisco, CA, USA.
Robin FatchUniversity of California, Department of Medicine, San Francisco, CA, USA.
Winnie R MuyindikeMbarara University of Sciences and Technology, Faculty of Medicine, Mbarara, Uganda.
Allen KekiibinaMbarara University of Sciences and Technology, Faculty of Medicine, Mbarara, Uganda.
Adam W CarricoUniversity of California, Department of Community Health Systems, San Francisco, CA, USA.
Sarah Woolf-KingUniversity of California, Department of Medicine, San Francisco, CA, USA.
Stephen ShiboskiUniversity of California, Department of Epidemiology and Biostatistics, San Francisco, CA, USA.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
URBAN ARCH (3/5) Uganda Cohort TB preventive therapy for HIV-infected alcohol users in Uganda: an evaluation of safety tolerability and adherenceU01AA020776 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2011 to 2021
$4.7M
Changes in Alcohol Consumption in HIV Positives in UgandaR01AA018631 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2010 to 2013
$2.0M
Training in Research Program on Alcohol Use by Persons with our at Risk for HIVK24AA022586 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2013 to 2023
$1.8M
Alcohol Use and High Risk Behavior Among HIV-Positive MenK01AA021671 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOOLF-KING, SARAH E · 2013 to 2017
$865k
NIAAA NIH HHS K01 AA021671NIAAA NIH HHS K01AA021671NIAAA NIH HHS K24 AA022586NIAAA NIH HHS K24AA022586NIAAA NIH HHS R01 AA018631NIAAA NIH HHS R01AA018631NIAAA NIH HHS U01 AA020776NIAAA NIH HHS U01AA020776NIAID NIH HHS P30 AI027763NIDDK NIH HHS P30 DK026743NIDDK NIH HHS P30DK026743NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

aimsWe examined whether unhealthy alcohol consumption, which negatively impacts HIV outcomes, changes after HIV care entry overall and by several factors. We also compared using phosphatidylethanol (PEth, an alcohol biomarker) to augment self-report to using self-report alone.

designA prospective 1-year observational cohort study with quarterly visits.

settingLarge rural HIV clinic in Mbarara, Uganda.

participantsA total of 208 adults (89 women and 119 men) entering HIV care, reporting any prior year alcohol consumption. MEASUREMENTS: Unhealthy drinking was PEth+ (≥ 50 ng/ml) or Alcohol Use Disorders Identification Test-Consumption+ (AUDIT-C+, over 3 months, women ≥ 3; men ≥ 4). We calculated adjusted odds ratios (AOR) for unhealthy drinking per month since baseline, and interactions of month since baseline with perceived health, number of HIV symptoms, antiretroviral therapy (ART), gender and self-reported prior unhealthy alcohol use.

findingsThe majority of participants (64%) were unhealthy drinkers (PEth+ or AUDIT-C+) at baseline. There was no significant trend in unhealthy drinking overall [per-month AOR: 1.01; 95% confidence interval (CI) = 0.94-1.07], while the per-month AORs were 0.91 (95% CI = 0.83-1.00) and 1.11 (95% CI = 1.01-1.22) when participants were not yet on ART and on ART, respectively (interaction P-value < 0.01). In contrast, 44% were AUDIT-C+; the per-month AORs for being AUDIT-C+ were 0.89 (95% CI = 0.85-0.95) overall, and 0.84 (95% CI = 0.78-0.91) and 0.97 (95% CI = 0.89-1.05) when participants were not on and were on ART, respectively.

conclusionsUnhealthy alcohol use among Ugandan adults entering HIV care declines prior to the start of anti-retroviral therapy but rebounds with time. Augmenting self-reported alcohol use with biomarkers increases the ability of current alcohol use measurements to detect unhealthy alcohol use.

Indexed as

AdultAlcohol DrinkingAmbulatory CareBiomarkersBreath TestsFemaleGlycerophospholipidsHIV InfectionsHumansMaleRisk-TakingRural HealthSelf ReportUgandaBiomarkersGlycerophospholipidsphosphatidylethanolAfricabiomarkerbrief interventionHIVphosphatidylethanolself-reporttrendUgandaunhealthy alcohol use

Identifiers

PMID26381193
PMCPMC4715487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.